President

Clinical Study Design and Management and Drug Delivery Development Professionals

Following a four-year tour in the U.S. Air Force, Mr. Mesa joined Rodana Research Corporation and remained continuously employed by its successor organizations, Survival Technology Inc., Meridian Medical Technologies Inc., King Pharmaceuticals Inc., and Pfizer.   During his 40 year tenure with these organizations, he became a highly experienced product development executive and an expert in the injectable drug delivery arena. Mr. Mesa is a named inventor on 20 plus patents involving drug delivery systems. 

In 2011, Mr. Mesa left Meridian/Pfizer and founded the Mesa Science Associates (MSA) consultancy, which provides a comprehensive array of pharmaceutical and drug product development solutions that MSA offers to researchers in the Federal Government, academic, and private research.

Management Expertise:

  • Pre-clinical and Clinical Program Management
  • Regulatory Submissions
  • Pre-filled and Pre-loaded Automatic Syringe Delivery Systems
  • Critical Component Supply Chain
  • Product transfer from Prototype to Full-Scale Production
  • Product Design and Development Processes
  • Design, Creation, and Implementation of Training Systems

MSA News

Dr. Kenneth Dretchen PhD has been appointed as a member of the Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Discovery Research Award Committee.

May 22, 2020 This committee review grant applications for Pre-doctoral, Post-doctoral and Research Starter Grants dealing with innovative approaches that…

Read More

Mesa Science Associates and Bryn Pharma Publish Second Pre-Clinical Study of a New Approach to Treating Anaphylaxis

The second in a series of three studies measured the pharmacokinetic and heart rate effects of intranasal epinephrine in dogs….

Read More

Mesa Science Associates and Bryn Pharma Publish Pre-Clinical Study of a New Approach to Treating Anaphylaxis

April 13, 2020 Mesa Science Associates Inc. (MSA) and Bryn Pharma LLC published the findings from the first of three…

Read More